NASDAQ:SAGE - SAGE Therapeutics Stock Price, News & Analysis

$162.00
+0.97 (+0.60 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
$159.49
Now: $162.00
$163.62
50-Day Range
$156.58
MA: $174.43
$190.88
52-Week Range
$79.88
Now: $162.00
$193.56
Volume231,500 shs
Average Volume403,214 shs
Market Capitalization$8.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.27 million
Book Value$23.29 per share

Profitability

Net Income$-372,880,000.00

Miscellaneous

Employees637
Market Cap$8.37 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.


SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($3.28) EPS for the quarter, topping analysts' consensus estimates of ($3.32) by $0.04. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.27 million. The business's revenue for the quarter was down 99.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.36) EPS. View SAGE Therapeutics' Earnings History.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for SAGE Therapeutics.

What price target have analysts set for SAGE?

14 analysts have issued 12 month target prices for SAGE Therapeutics' stock. Their forecasts range from $80.00 to $261.00. On average, they expect SAGE Therapeutics' share price to reach $200.2727 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

What is the consensus analysts' recommendation for SAGE Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

News coverage about SAGE stock has trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SAGE Therapeutics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for SAGE Therapeutics.

Who are some of SAGE Therapeutics' key competitors?

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), Twitter (TWTR), Johnson & Johnson (JNJ), Celgene (CELG) and Gilead Sciences (GILD).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (15.30%), Vanguard Group Inc. (8.92%), Jennison Associates LLC (5.72%), BlackRock Inc. (5.32%), Invesco Ltd. (3.91%) and Janus Henderson Group PLC (3.66%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

Which institutional investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Farallon Capital Management LLC, Strs Ohio, Senator Investment Group LP, Candriam Luxembourg S.C.A. and Bank of America Corp DE. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

Which institutional investors are buying SAGE Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Jennison Associates LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, BlackRock Inc., Amundi Pioneer Asset Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $162.00.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $8.37 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is http://www.sagerx.com/.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  757
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel